drugset / Trial / NCT02628704
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
RandomizedParallel-groupTriple-blindTreatment
Summary
Double-blind study will compare the efficacy and assess safety of selinexor plus carfilzomib (Kyprolis®) plus low-dose dexamethasone versus placebo plus carfilzomib plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2015-12
- Primary completion
- 2017-06
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Background | Carfilzomib | Other / unclassified | — | Intravenous |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |